U.S. SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C.  20549

                           FORM 10-QSB

     [ X ]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

     For the quarterly period ended September 30, 2001

     [   ]     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

     For the transition period from    to

                 Commission File No.  000-15243

                 VITAL HEALTH TECHNOLOGIES, INC.
     (Exact name of small business issuer as specified in its
                            charter)

           Minnesota                        41-1618186
(State or Other Jurisdiction of           (IRS Employer
Incorporation or Organization)         Identification No.)

         855 Village Center Drive, North Oaks, MN 55127
            (Address of Principal Executive Offices)

                         (651) 238-8636
                   (Issuer's telephone number)

       3805 Centre Point Drive North, Roseville, MN 55113
(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Exchange Act during the
preceding 12 months (or for such shorter period that the issuer
was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [ X] No [  ]

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
DURING THE PRECEDING FIVE YEARS:

Check whether the registrant has filed all documents and reports
required to be filed by Sections 12, 13, or 15(d) of the
Exchange Act subsequent to the distribution of securities under
a plan confirmed by a court. Yes [  ]  No  [  ]

APPLICABLE ONLY TO CORPORATE ISSUERS:
State the number of shares outstanding of each of the issuer's
classes of common equity, as of September 30, 2001: 2,839,898
shares of common stock.

Transitional Small Business Format:  Yes [   ]  No [ X ]

<PAGE>
                           FORM 10-QSB
                 VITAL HEALTH TECHNOLOGIES, INC.

                              INDEX
                                                       Page
PART I.     FINANCIAL INFORMATION                         3

Item 1      Financial Statements                          3

Item 2      Management's Discussion and Analysis of       6
            Financial Condition and Plan of Operation

PART II.    OTHER INFORMATION                             8

Item 6      Exhibits and Reports on Form 8-K              8

SIGNATURES                                                9

                                     2
<PAGE>

Item 1. Financial Information

                   VITAL HEALTH TECHNOLOGIES, INC.
                    (A Development Stage Company)

                           BALANCE SHEETS
                             (Unaudited)

                                          September 30,   December 31,
                                               2001           2000
              ASSETS

Current assets:
 Cash                                      $      243   $      9,143
 Inventory                                      1,035          3,073
 Prepaid expenses                                   0          7,282

      Total current assets                      1,278         19,498

Furniture and equipment                         6,677          6,677
Less accumulated depreciation                   1,623            162
      Net furniture and equipment               5,054          6,515

      Total assets                        $     6,332   $     26,013

  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:
 Accounts payable and accrued expenses    $     7,905   $     10,232
 Notes payable - convertible                   95,000              0

      Total current liabilities               102,905         10,232

Stockholders' equity (deficit):
 Undesignated stock: 5,000,000 shares
   authorized; none issued and outstanding          0              0
 Common stock: $.01 par value; 50,000,000
   shares authorized; shares issued and
   outstanding 2,839,898 in 2001 and 2000      28,399         28,399
 Additional paid-in capital                11,821,224     11,820,674
 Accumulated deficit                      (11,793,637)   (11,793,637)
 Deficit accumulated during the
   development stage                         (152,559)       (39,655)

     Total stockholders' equity (deficit)     (96,573)        15,781

      Total liabilities and
        Stockholders' equity (deficit)  $       6,332    $    26,013

                 See Notes to Financial Statements.

                                     3
<PAGE>

                   VITAL HEALTH TECHNOLOGIES, INC.
                    (A Development Stage Company)

                      STATEMENTS OF OPERATIONS
                             (Unaudited)
<TABLE>
<CAPTION>

                                       Three Months Ended      Nine Months Ended
                                          September 30,           September 30,
                                        2001       2000        2001         2000
<S>                                <C>           <C>         <C>          <C>
Revenues                           $        0    $      0    $   2,907    $       0

Cost of sales                               0           0          (77)           0

General and administrative expenses   (15,523)    (71,195)    (108,681)     (71,210)

Interest expense                       (2,271)     (4,323)      (5,053)      (4,323)

Inventory valuation allowance          (2,000)          0       (2,000)           0

Debt forgiveness                            0      83,863            0       83,863

Income tax expense                          0           0            0            0

Net income (loss)                     (19,794)      8,345     (112,904)       8,330

Other comprehensive income (loss)           0           0            0            0

Comprehensive income (loss)        $  (19,794)   $  8,345    $(112,904)   $   8,330

Basic earnings (loss) per share    $     (.01)   $    .02    $    (.04)   $     .02

Weighted average number of
 shares outstanding                 2,839,898     419,833    2,839,898      419,833
</TABLE>
See Notes to Financial Statements.

                                     4
<PAGE>

                   VITAL HEALTH TECHNOLOGIES, INC.
                    (A Development Stage Company)

                      STATEMENTS OF CASH FLOWS
                     Increase (Decrease) In Cash
                             (Unaudited)

                                                Nine Months Ended
                                                  September 30,
                                            2001        2000
Cash flows from operating activities:
  Net income (loss)                                 $ (112,904)  $    8,330
  Adjustments to reconcile net income (loss)
    to cash flows from operating activities:
    Debt forgiveness                                         0       (8,344)
    Warrants issued for consulting services                550            0
    Depreciation                                         1,461            0
    Inventory valuation allowance                        2,000            0
    Inventory                                               38            0
    Prepaid expenses                                     7,282            0
    Accounts payable and other current liabilities      (2,327)          14
Cash flows from operating activities                  (103,900)           0

Cash flows from financing activities:
 Issuance of convertible notes payable                 95,000             0

Cash flows from investing activities                        0             0

Increase (decrease) in cash                            (8,900)            0

Cash:
  Beginning of year                                     9,143             0

  End of year                                     $       243     $       0


Supplemental cash flow information:
Interest paid                                     $         0     $       0
Income taxes paid                                 $         0     $       0

Summary of non cash activity:

In 2000, the Company received debt forgiveness totaling $83,863.
$75,519 of this debt was incurred and forgiven in 2000.

Warrants to purchase 55,000 shares of the Company's common stock at
$.05 per share were issued by the Company in January and March 2001
as part of consulting agreements.  These warrants were valued at $.01
per share.

                 See Notes to Financial Statements.

                                     5
<PAGE>

NOTES TO FINANCIAL STATEMENTS

A.      BASIS OF PRESENTATION

The   accompanying  unaudited  financial  statements  have   been
prepared   in  accordance  with  generally  accepted   accounting
principles  for  interim  financial  information  and  with   the
instructions  to  Form 10-QSB and Article 10 of  Regulation  S-X.
Accordingly,  they  do  not include all of  the  information  and
footnotes  required  by generally accepted accounting  principles
for complete financial statements.  In the opinion of management,
all   adjustments  (consisting  of  normal  recurring   accruals)
considered necessary for a fair presentation have been  included.
Operating  results for the nine-month period ended September  30,
2001  are not necessarily indicative of the results that  may  be
expected  for  the  year ended December 31,  2001.   For  further
information,  refer  to  the financial statements  and  footnotes
thereto included in the Company's Form 10-KSB for the year  ended
December 31, 2000.

Nature of Business

The Company was incorporated on April 1, 1960, under the laws  of
the  State  of  Minnesota.  On September 26,  2000,  the  Company
changed its name to Vital Health Technologies, Inc.  Formerly the
Company was known as Vital Heart Systems, Inc.

In  November  1993,  the  Company  ceased  the  majority  of  its
operations.  At January 1, 1994, the Company was deemed  to  have
reentered  the development stage.  From 1994 to 1997 the  Company
had  only  limited operations as it tried to complete the  design
and  marketing  of  a non-invasive, stress-free  coronary  artery
disease  (CAD) detection device.  In 1997 the Company ceased  all
operations.

In  1998  and  1999  the Company worked with a Minnesota  venture
capital  firm,  Aurora Capital Management,  LLC  (Aurora)  and  a
Minnesota  entity  with  compatible  business  operations,  Vital
Health Technologies, LLC (VHT-LLC) in an effort to revitalize the
Company.  These dealings ultimately led to the acquisition of VHT-
LLC's assets on December 1, 2000.

Development Stage Company

On  January 1, 1994, the Company was deemed to have reentered the
development  stage.  Since that date the Company has devoted  the
majority of its efforts to: maintenance of the corporate  status;
settlement of liabilities; and the search for a viable method  of
operations and/or merger candidate.

In 1998, 1999, 2000 and 2001 the Company has been fully dependent
on VHT-LLC and Aurora for the maintenance of its corporate status
and  to  provide  all managerial assistance and  working  capital
support for the Company.

In  November 2000, the Company satisfied the last of its judgment
creditors.   In  October 2000, the Company reached  an  agreement
with  VHT-LLC to settle its indebtedness to VHT-LLC  for  400,989
shares of the Company's common stock .  On December 1, 2000,  the
Company  acquired  all  of the assets of  VHT-LLC  for  2,000,000
shares  of  the  Company's common stock.  The Company  is  moving
forward   with  development  of  its  core  technology  (variance
cardiography).   The Company is focusing efforts  on  partnership
agreements  with  larger  medical device  companies  and  raising
capital  from  institutional investors  and  venture  funds.  The
Company  has  also been contemplating raising capital  through  a
private  placement  or  rights offering of the  Company's  common
stock.

                                     6
<PAGE>

Management feels it will be successful in these efforts and  that
it will achieve profitable operations.  Failure of the company to
achieve  these goals could result in it being unable to  continue
as a going concern.  No estimate can be made of the range of loss
that is reasonably possible should the Company be unsuccessful.

Item 2.  Managements Discussion and Analysis of Financial
Condition and Plan of Operation

Three Months Ended September 30, 2001 and 2000

   The Company generated no revenue for the three months ended
September 30, 2001, as compared to no revenue for the three
months ended September 30, 2000.  Cost of sales for the three
months ended September 30, 2001 and 2000 were $0 and $0,
respectively.  The Company generated revenue of $2,907 for the
nine months ended September 30, 2001, as compared to no revenue
for the nine months ended September 30, 2000.  Cost of sales for
the nine months ended September 30, 2001 and 2000 were $77 and
$0, respectively.

   General and administrative expenses for the three months ended
September 30, 2001 were $15,523, as compared to $71,195 in the
same period of 2000.  General and administrative expenses for the
nine months ended September 30, 2001 were $108,681, as compared
to $71,210 in the same period of 2000.  This large increase in
expenses is attributable primarily to technology development and
legal and accounting expenses incurred to bring the Company
current in its reporting obligations under the Securities
Exchange Act of 1934.

   The Company had interest expense in the amount of $2,271 for
the three months ended September 30, 2001, as compared to $4,323
interest expense for the three months ended September 30, 2000.
The Company had interest expense in the amount of $5,053 for the
nine months ended September 30, 2001, as compared to $4,323
interest expense for the nine months ended September 30, 2000.
The Company recognized a gain from debt forgiveness in the first
three months of September 2000, which did not recur in the three
months ended September 30, 2001.

   As a result of the foregoing, the Company realized a net loss
of $19,794 for the three months ended September 30, 2001, as
compared to net income of $8,345 for the same period in 2000.
As a result of the foregoing, the Company realized a net loss of
$112,904 for the nine months ended September 30, 2001, as
compared to net income of $8,330 for the same period in 2000.

Liquidity and Capital Resources

   At September 30, 2001, the Company had a working capital
deficit of $101,627, as compared to a working capital of $9,266
at September 30, 2000.  The substantial change in working capital
is attributable to the Company's use of debt financing to fund
current activities.

   To reduce operating expenses the Company negotiated a lease
termination agreement for approximately 2,000 square feet of
space at the Roseville, Minnesota location.  The termination of
the lease will save the Company approximately $3,500 per month
beginning October 1, 2001.  The Company will retain 420 square
feet of space at the Shoreview, Minnesota location and will be
seeking additional space when the Company has sufficient capital
to implement its plan of operations.  The Company received a loan
in the amount of $2,500 from Focus Tech Investments Inc. on
September 10, 2001 and another $2,500 from its primary officer
William Kieger on September 24, 2001.  Both loans accrue interest
at 10% per annum and are scheduled to come due 12 months from
issue.

                                     7
<PAGE>
   The Company has been actively seeking partnership
opportunities with larger medical technology companies in the
industry for financing along with venture firms and private
investors.

   If we are unable to locate alternative financing, our ability
to further implement our business plan and sustain existing
operations will be substantially impaired and our continuation as
a going concern is unlikely.

   Until Vital Health receives additional outside financing to
fund its capital commitments, its operations will be limited to
those that can be effected through its officers, directors and
consultants.  Our primary officer has agreed to perform services
without compensation until the Company has sufficient resources
to pay him.  He is providing services on a full time basis.  Many
of our outside consultants have accepted warrants for services
rendered, but there is no assurance they will continue to do so
in the future.  In the event Vital Health generates revenue from
product sales and financing from outside sources sufficient to
fund operations, Vital Health expects to enter into more formal
compensation arrangements with it officers and seek employees
with abilities that will advance our business objectives.

     Our plan for the next 12 months is to handle the
administrative and reporting requirements of a public company;
and:

     Medical Application

     Work with HealthEast Midway Clinic to perfect clinical
     application of Variance Cardiograph

     Conduct a longitudinal study of the previously tested
     subjects over the past 8-12 years to assess predictability
     of Variance Cardiography

     Apply for FDA market clearance of the Variance Cardiograph
     in medical diagnostic applications,

     Seek out a strategic partnership agreement with a medical
     devise distributor to implement manufacturing and marketing
     of the Variance Cardiograph to health care providers, and

     Apply for health care provider reimbursement through
     insurance and government programs for the Variance
     Cardiograph diagnostic procedure to facilitate marketing;

     Vital Health is going to seek up to $2,000,000 in financing
over the next 12 months to fund its proposed operations over the
next 12 to 24 months.  Of this amount, $1,350,000 represents
general and administrative expenses and working capital reserves,
which is intentionally high because of the uncertainties we face
in implementing this new business.  In addition, in the event a
sales agent is utilized to complete the private placement
offering, the company has budgeted $260,000 for commissions and
expense reimbursement.  The estimated use of the remaining
$650,000 is as follows:


Legal and professional fees     $   50,000
FDA Application                 $  100,000
Research and Development        $  200,000
Marketing                       $  200,000
Clinical Studies                $  100,000

                                     8
<PAGE>


The foregoing figures are only estimates, and actual use of any
capital we obtain may vary substantially as the implementation of
our business unfolds.

Forward-Looking Statement Notice

   When used in this report, the words "may," "will," "expect,"
"anticipate," "continue," "estimate," "project," "intend," and
similar expressions are intended to identify forward-looking
statements within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of
1934 regarding events, conditions, and financial trends that may
affect the Company's future plans of operations, business
strategy, operating results, and financial position.  Persons
reviewing this report are cautioned that any forward-looking
statements are not guarantees of future performance and are
subject to risks and uncertainties and that actual results may
differ materially from those included within the forward-looking
statements as a result of various factors.  Such factors are
discussed above and also include general economic factors and
conditions that may directly or indirectly impact the Company's
financial condition or results of operations.

                   PART II.  OTHER INFORMATION

Item 6 - Exhibits and Reports on Form 8-K

Reports on Form 8-K

   None

Exhibits

   Copies of the following documents are included as exhibits to
this report pursuant to Item 601 of Regulation S-B.

SEC Ref No.         Title of Document                         Location

10.1           Convertible Promissory Note
                 with Focus Tech Investments, Inc.             Attached

10.2           Convertible Promissory Note
                 with William Kieger                           Attached

                           SIGNATURES

   In accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

                                     Vital  Health  Technologies, Inc.

Date: November 2, 2001               By /s/ William  Kieger, President
                                      Chief Executive and Financial Officer

                                     9
<PAGE>